Literature DB >> 15247008

Total deletion of in vivo telomere elongation capacity: an ambitious but possibly ultimate cure for all age-related human cancers.

Aubrey D N J de Grey1, F Charles Campbell, Inderjeet Dokal, Leslie J Fairbairn, Gerry J Graham, Colin A B Jahoda, Andrew C G Porterg.   

Abstract

Despite enormous effort, progress in reducing mortality from cancer remains modest. Can a true cancer "cure" ever be developed, given the vast versatility that tumors derive from their genomic instability? Here we consider the efficacy, feasibility, and safety of a therapy that, unlike any available or in development, could never be escaped by spontaneous changes of gene expression: the total elimination from the body of all genetic potential for telomere elongation, combined with stem cell therapies administered about once a decade to maintain proliferative tissues despite this handicap. We term this therapy WILT, for whole-body interdiction of lengthening of telomeres. We first argue that a whole-body gene-deletion approach, however bizarre it initially seems, is truly the only way to overcome the hypermutation that makes tumors so insidious. We then identify the key obstacles to developing such a therapy and conclude that, while some will probably be insurmountable for at least a decade, none is a clear-cut showstopper. Hence, given the absence of alternatives with comparable anticancer promise, we advocate working toward such a therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247008     DOI: 10.1196/annals.1297.026

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  2 in total

1.  Like it or not, life-extension research extends beyond biogerontology.

Authors:  Aubrey D N J de Grey
Journal:  EMBO Rep       Date:  2005-11       Impact factor: 8.807

2.  You don't need a weatherman: famines, evolution, and intervention into aging.

Authors:  Michael J Rae
Journal:  Age (Dordr)       Date:  2006-05-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.